TIDMOHGR
RNS Number : 4710V
One Health Group PLC
04 December 2023
4 December 2023
One Health Group plc
("One Health" or "OHG" or the "Group")
Half Year results for the Six Months to 30 September 2023
(unaudited)
& Declaration of Interim Dividend
Underlying EBITDA 48% ahead of prior year
New surgical capacity coming on stream to meet massive demand
for NHS-funded surgery
One Health (AQSE: OHGR), a provider of NHS-funded medical
procedures, is pleased to announce its unaudited interim results
for the six months ended 30 September 2023.
Financial Highlights
The Group has performed well in the first half with excellent
increases in revenues, profitability and cash. The interim dividend
has been increased by 22% to 2.03p per share.
Financial Summary Current period Prior Year Increase %
Turnover GBP11.06m GBP9.83m +13%
---------------- ------------ -----------
Underlying EBITDA GBP0.787 m GBP0.532 m + 48 %
---------------- ------------ -----------
Underlying EPS 5.15 pence 3.91 pence + 32%
---------------- ------------ -----------
Cash balance GBP3.64 m GBP2.68 m + 36 %
---------------- ------------ -----------
Interim dividend 2.03 pence 1.66 pence + 22 %
---------------- ------------ -----------
Declaration of Interim Dividend
One Health Group plc is pleased to announce that the Board of
Directors has declared an interim dividend at the rate of 2.03
pence per share, to be paid on on 12 January 2024 to shareholders
on the register as at close of business on 22 December 2023. The
ex-dividend date will be 21 December 2023.
Operational Highlights
-- New patient referrals increased by 12%
-- Surgical procedures carried out on some 3,000 NHS patients, a 7% increase
-- Surgical activity started at a new independent hospital in a new geographical area
-- Additional capacity sourced within two current independent hospital partners
-- Attracted 15 new clinicians to the business to support growth.,
-- Increased demand for Waiting List transfers with two new NHS Trust contracts
-- National media campaign launched by the NHS to promote
knowledge of 'Patient Choice' will increase GP referrals.
Planned developments & Potential Profit Impact
-- Another 30 clinicians in the application process.
-- Surgical hubs are being actively pursued to increase the
Group's surgical capacity to help to satisfy the demand from the
NHS.
Review of the period
Operationally, 2023 has seen a further increase in the national
NHS waiting list and industrial action causing disruption to NHS
patients care caused by cancelations. As a result demand for
support by the independent sector remained high during the first
half of the year. During the period we saw an increased demand for
waiting list transfers and direct referrals from NHS Trusts. The
Group has attracted 15 new clinicians to the Group into new
geographical areas and continues to expand surgical capacity in
existing areas, meaning One Health is well placed to support the
NHS in the second half of the year, traditionally our busiest
period. The Group continues to work closely with NHS trusts to
support the reduction of waiting lists for elective care.
From a financial perspective One Health has performed well in
the first half of the year. Financial performance is in line with
management and market expectations and as we enter our busiest
period of the year, we are confident we will achieve full year
revenue and profit expectations.
Cash reserves at the end of September 2023 of GBP3.64m support
ongoing investment in growth and our progressive dividend policy.
The Board is therefore declaring an increased interim dividend of
2.03p per Ordinary Share (H1 22/23: 1.66p per share) to be paid on
12 January 2024 to shareholders on the register as at close of
business on 22 December 2023. Last year's interim dividend was
agreed by the Board before the business was listed and was paid in
January 2023. Following the IPO in November 2022, the Group is
adjusting the profile of dividend payments and expects the interim
dividend to represent 1/3 of the full year dividend going
forward.
Adam Binns, Chief Executive Officer, said:
"One Health has performed well in the first six months of the
financial year, with turnover up 13% to GBP11.06m, underlying
EBITDA up 48% to nearly GBP0.8m and new patient referrals up 12% at
6,094.
"Notably these referrals include an increasing number of NHS
patients transferring to One Health from local Trust waiting lists
to help them reduce their internal waiting lists, with two new
contracts secured in H1. The Trust transfer activity is in addition
to patients received through the traditional route by choosing to
be referred to One Health through 'Patient Choice' after visiting
their GP.
"We are pleased with performance in the first half of the year
and expect to achieve our year end forecasts."
About One Health Group
One Health engages over 100 NHS Consultants who sub-specialise
in the various surgeries offered by the Group, through a growing
network of community-based outreach clinics and surgical operating
locations. In the year to March 2023 One Health serviced almost
12,000 new patients, through over 29,000 consultations and
performed 5,790 surgical procedures. One Health uses surgeons and
anaesthetists that are mostly employed by the NHS, on a consultancy
basis. It currently works with over 100 professionals across seven
hospitals and over 30 CQC registered clinics.
One Health's activities are focused on areas where the patient
needs are under-supplied by the local NHS service as well as
locations where population density is relatively high, and the
level of private medical insurance is relatively low. One Health
has also sought to expand geographically from its head office in
Sheffield, South Yorkshire into neighbouring counties, which meet
the required criteria. Currently, the Group's activities are
focused in Yorkshire, Lincolnshire, Derbyshire, Nottinghamshire and
Leicestershire. Revenue in the year to 31 March 2023 was derived
from 60 Clinical Commissioning Groups in addition to contracts
directly with NHS hospitals to manage their internal waiting
lists.
One Health's business model has focused to date on four main
areas: being Spine, Orthopaedics, General Surgery and Gynaecology.
The split of inpatient procedures in the year to 31 March 2023 was
as follows: Orthopaedics 44% Spine 27% General Surgery 22%
Gynaecology 7%.
Orthopaedics and Spine are particularly attractive areas for One
Health as the Directors believe that they benefit from powerful
growth drivers in terms of an ageing demographic, physical
inactivity and an increasing proportion of the population being
categorised as obese. Within orthopedics, the most common surgeries
performed by One Health are knee and hip replacements.
* ( https://www.onehealth.co.uk/investors )
The Directors of One Health Group plc accept responsibility for
the contents of this announcement.
For more information, please contact:
One Health Group plc via Square1 Consulting
Oberon Capital - AQSE Corporate Adviser and Broker +44 203 179 5300
Nick Lovering
Mike Seabrook
Adam Pollock
Square1 Consulting +44 207 929 5599
David Bick +44 7831 381201
Consolidated Statement of Income and Retained Earnings
For the six months to 30 September 2023
6 months to 6 months to Year to
30 September 30 September
2023 2022 31 March 2023
GBP GBP GBP GBP GBP GBP
TURNOVER 11,062,281 9,831,204 20,501,807
Cost of Sales (9,104,582) (8,184,746) (16,865,547)
------------ ------------ -------------
GROSS PROFIT 1,957,699 1,646,458 3,636,260
Administrative
Expenses (1,278,873) (1,298,153) (3,051,263)
Share option
charge 0 (119,487) (360,443)
------------ ------------ ------------
Adjusted
Administrative
Expenses (1,278,873) (1,417,640) (3,411,706)
Other Operating
Income 54,600 47,571 104,209
------------ ------------ -------------
OPERATING PROFIT 733,426 276,389 328,763
Loss on
revaluation
of investment
property (170,620)
Interest
receivable
and similar
income 35,775 3,317 18,909
------------ ------------ ------------
35,775 3,317 (151,711)
Interest payable
and similar
expenses (62,483) (23,848) (96,907)
------------ ------------ -------------
PROFIT BEFORE
TAXATION 706,718 255,858 80,145
Tax on profit (165,709) (46,616) (19,842)
PROFIT FOR THE
FINANCIAL
PERIOD 541,009 209,242 60,303
============ ============ =============
Other
comprehensive
income 0 0 195,339
TOTAL
COMPREHENSIVE
INCOME FOR THE
PERIOD 541,009 209,242 255,642
============ ============ =============
Profit
attributable
to owners of the
parent 541,009 209,242 255,642
Underlying EBITDA* 786,550 532,128 1,532,386
Retained earnings
at beginning of
period 4,916,111 5,012,465 5,012,465
Profit
attributable
to owners of the
parent 541,009 209,242 60,303
Transfers to
reserves 0 0 553,698
Dividends (413,733) (560,280) (710,355)
------------ ------------ -------------
RETAINED EARNINGS
OF THE GROUP 5,043,387 4,661,427 4,916,111
------------ ------------ -------------
Earnings per
share
Underlying* 5.15 p 3.91 p 11.29 p
Basic 5.15 p 2.09 p 0.60 p
Diluted 5.06 p 2.09 p 0.58 p
*Excludes costs relating to exceptional items as detailed in
Note 3
Consolidated Statement of Financial Position
As at 30 September 2023
As at As at As at
30 September 2023 30 September 2022 31 March 2023
GBP GBP GBP GBP GBP GBP
FIXED ASSETS
Tangible Assets 1,646,788 1,109,100 1,346,897
Investment Property 1,691,285 1,861,905 1,691,285
------------ ------------ ------------
3,338,073 2,971,005 3,038,182
CURRENT ASSETS
Debtors 4,582,583 5,842,346 4,326,079
Cash at bank and at hand 3,642,649 2,683,143 3,284,548
---------- ---------- ----------
8,225,232 8,525,489 7,610,627
Amounts falling due within one year 4,627,816 5,260,976 3,833,191
---------- ---------- ----------
NET CURRENT ASSETS 3,597,416 3,264,513 3,777,436
TOTAL ASSETS LESS CURRENT
LIABILITIES 6,935,489 6,235,518 6,815,618
Amounts due after more than one
year (1,063,717) (1,059,031) (1,071,122)
Provisions for liabilities (59,794) 2,935 (59,794)
------------ ------------ ------------
NET ASSETS 5,811,978 5,179,422 5,684,702
============ ============ ============
CAPITAL AND RESERVES
Called up share capital 52,551 10,000 52,551
Share premium 365,448 0 365,448
Revaluation reserve 107,934 83,215 107,934
Share option reserve 242,658 424,780 242,658
Retained earnings 5,043,387 4,661,427 4,916,111
------------ ------------ ------------
SHAREHOLDERS' FUNDS 5,811,978 5,179,422 5,684,702
============ ============ ============
Consolidated Cashflow Statement
For the six months to 30 September 2023
6 months to 6 months to Year to
30 September 2023 30 September 2022 31 March 2023
GBP GBP GBP
Cash flows from operating activities
Cash generated from operations 1,159,301 (375,482) 209,363
Interest paid (62,483) (23,848) (96,907)
Tax paid 0 0 (152,353)
------------------- ------------------- ---------------
Net cash from operating activities 1,096,918 (399,330) (39,897)
Cash flows from investing activities
Purchase of tangible fixed assets (353,354) (19,144) (23,840)
Sale of tangible fixed assets 0 0 1,061
Interest received 35,775 3,317 18,909
Net cash from investing activities (317,579) (15,827) (3,870)
Cash flows from financing activities
Loan repayments in year (26,400) (26,400) (52,800)
Accrued loan interest 18,995 0 38,491
Share issue 0 0 367,999
Equity dividends paid (413,733) (560,280) (710,355)
------------------- ------------------- ---------------
Net cash from financing activities (421,138) (586,680) (356,665)
=================== =================== ===============
(Decrease)/increase in cash and cash equivalents during
the period 358,101 (1,001,837) (400,432)
Cash and cash equivalents at beginning of period 3,284,548 3,684,980 3,684,980
Cash and cash equivalents at end of period 3,642,649 2,683,143 3,284,548
One Health Group plc
Notes to the Interim Results
for the Period 1 April 2023 to 30 September 2023
1. STATUTORY INFORMATION
One Health is a public Group, limited by shares, registered in
England and Wales. The Group's registered number is 04201068 and
registered office address is 131 Psalter Lane, Sheffield, South
Yorks, S11 8UX.
The Interim Results have been reviewed, not audited, and were
approved by the Board of Directors on 1(st) of December 2023.
2. ACCOUNTING POLICIES
Basis of preparing the Interim Results
These Interim Results have been prepared in accordance with
Financial Reporting Standard 102 "The Financial Reporting Standard
applicable in the UK and Republic of Ireland" and the Companies Act
2006. The Interim Results have been prepared under the historical
cost convention as modified by the revaluation of certain
assets.
The Interim Results have been prepared on a going concern basis.
The Directors have reviewed and considered relevant information,
including the annual budget and future cash flows in making their
assessment. The Directors have tested their cash flow analysis to
account for the impact on their business of possible scenarios,
alongside the measures that they can take to mitigate the impact of
possible scenarios. Based on these assessments, given the measures
that could be undertaken to mitigate the current adverse
conditions, and the current resources available, the Directors have
concluded that they can continue to adopt the going concern basis
in preparing the annual report and accounts.
The accounts are presented in Sterling currency and rounded to
the nearest pound.
Financial Reporting Standard 102 - reduced disclosure
exemptions
The Group has taken advantage of the exemption from disclosing
the Group key management personnel compensation, as required by FRS
102 paragraph 33.7.
Basis of consolidation
The Interim Results include the interim financial information of
the Group and all of its subsidiary undertakings, together with the
Group's share of the results of associates made up to 30
September.
A subsidiary is an entity controlled by the Group. Control is
the power to govern the financial and operating policies of an
entity so as to obtain benefits from its activities. Where the
Group owns less than 50% of the voting powers of an entity but
controls the entity by virtue of an agreement with other investors
which give it control of the financial and operating policies of
the entity, it accounts for that entity as a subsidiary.
Where a subsidiary has different accounting policies to the
Group, adjustments are made to those subsidiary financial
statements to apply the Group's accounting policies when preparing
the consolidated Interim Results.
Any subsidiary undertakings or associates sold or acquired
during the year are included up to, or from, the dates of change of
control or change of significant influence respectively.
All intra-Group transactions, balances, income, and expenses are
eliminated on consolidation. Adjustments are made to eliminate the
profit or loss arising on transactions with associates to the
extent of the Group's interest in the entity.
2. ACCOUNTING POLICIES - continued
Significant judgements and estimates
In preparing the Interim Results it is necessary to make certain
judgements, estimates and assumptions that affect the amounts
recognised in the financial information presented in the Interim
Results. These assumptions are reassessed annually as part of the
interim and year end accounts preparation process.
The critical judgments that the directors have made in the
process of applying the Group's accounting policies that have the
most significant effect on the Interim Results are discussed
below.
i) Assessing indicators of impairment
In assessing whether there have been any indicators of
impairment assets, the directors have considered both external and
internal sources of information such as market conditions,
counterparty credit ratings and experience of recoverability. There
have been no indicators of impairments identified during the
current financial year.
Key sources of estimation uncertainty
i) Determining useful economic lives of tangible fixed assets
The Group depreciates tangible fixed assets over their estimated
useful lives. The estimation of the useful lives of assets is based
on historic performance as well as expectations about future use
and therefore requires estimates and assumptions to be applied by
management. The actual lives of these assets can vary depending on
variety of factors, including technological innovation, product
life cycles and maintenance programmes.
The judgment is applied by management when determining the
residual values for tangible fixed assets. When determining the
residual value management aim to assess the amount that the Group
would currently obtain for the disposal of the asset, if it were
already of the condition expected at the end of its useful life.
Where possible this is done with reference to external market
prices.
(ii) Recoverability of debtors
The Group establishes a provision for debtors that are estimated
not to be recoverable. When assessing recoverability, the directors
have considered factors such as the ageing of debtors, past
experience of recoverability and the credit profile of individual
or Groups of customers.
Turnover
Turnover is measured at the fair value of the consideration
received or receivable, excluding discounts, rebates, value added
tax and other sales taxes.
Turnover consists of the provision of medical and clinical
services, sale of medical implants, and recharge of direct costs
incurred. All turnover is generated in the United Kingdom.
Dividend income is recognised when the right to receive payment
is established.
Tangible fixed assets
Tangible assets are started at cost less accumulated
depreciation and accumulated impairment losses. Depreciation on
other assets is provided at the following annual rates in order to
write off the cost, less estimated residual value of each asset
over its estimated useful life.
Freehold property 2% straight line
Long leasehold 10% straight line
Plant and machinery 15% straight line
Fixtures and fittings 20% straight line
Computer equipment 25% straight line
2. ACCOUNTING POLICIES - continued
The assets' residual values. useful lives and depreciation
methods are reviewed, if appropriate at the end of each reporting
period. The effect of any change is accounted for
prospectively.
Investment property
Investment property is shown at most recent valuation. Any
aggregate surplus or deficit arising from changes in fair value is
recognised in the Statement of Income and Retained Earnings.
Investment in a subsidiary company
Investment in subsidiary company is held at cost less
accumulated impairment losses.
Financial instruments
The Group has elected to apply the provisions of Section 11
'Basic Financial Instruments' and Section 12 'Other Financial
Instruments Issues' of FRS 102 to all of its financial
instruments.
Basic financial assets, including trade and other receivables,
cash and bank balances and investments in commercial paper, are
initially recognised at transaction price, unless the arrangement
constitutes a financing transaction, where the transaction is
measured at the present value of the future receipts discounted at
a market rate of interest. Such assets are subsequently carried at
amortised cost using the effective interest method.
At the end of each reporting period financial assets measured at
amortised cost are assessed for objective evidence of impairment.
If an asset is impaired the impairment loss is the difference
between the carrying amount and the present value of the estimated
cash flows discounted at the asset's original effective interest
rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an
event occurring after the impairment was recognised, the impairment
is reversed. The reversal is such that the current carrying amount
does not exceed what the carrying amount would have been had the
impairment not previously been recognised. The impairment reversal
is recognised in profit or loss.
Financial assets are derecognised when (a) the contractual
rights to the cash flows from the asset expire or are settled or
(b) substantially all the risks and rewards of the ownership of the
asset are transferred to another party or (c) control of the asset
has been transferred to another party who has the practical ability
to unilaterally sell the asset to an unrelated third party without
imposing additional restrictions.
Basic financial liabilities, including trade and other payables,
bank loans, loans from fellow Group companies and preference shares
that are classified as debt, are initially recognised at
transaction price, unless the arrangement constitutes a financing
transaction, where the debt instrument is measured at the present
value of the future receipts discounted at a market rate of
interest. Debt instruments are subsequently carried at amortised
cost, using the effective interest rate method.
Fees paid on the establishment of loan facilities are recognised
as transaction costs of the loan to the extent that it is probable
that some or all of the facility will be drawn down. In this case,
the fee is deferred until the draw-down occurs. To the extent there
is no evidence that it is probable that some or all of the facility
will be drawn down, the fee is capitalised as a pre-payment for
liquidity services and amortised over the period of the facility to
which it relates.
Trade payables are obligations to pay for goods or services that
have been acquired in the ordinary course of business from
suppliers. Accounts payable are classified as current liabilities
if payment is due within one year or less. If not, they are
presented as non-current liabilities. Trade payables are recognised
initially at transaction price and subsequently measured at
amortised cost using the effective interest method.
Financial liabilities are derecognised when the liability is
extinguished, that is when the contractual obligation is
discharged, cancelled or expires.
2. ACCOUNTING POLICIES - continued
Cash and cash equivalents
Cash and cash equivalents include cash in hand, deposits held at
call with banks, other short-term highly liquid investments with
original maturities of three months or less and bank overdrafts.
Bank overdrafts are shown within borrowings in current
liabilities.
Distributions to equity holders
Dividends and other distributions to the company's shareholders
are recognised as a liability in the Interim Results in the period
in which the dividends and other distributions are approved by the
company's shareholders. These amounts are recognised in the
statement of changes in equity.
Related party transactions
The Group discloses transactions with related parties which are
not wholly owned with the same Group. It does not disclose
transactions with its parent or with members of the same Group that
are wholly owned.
Taxation
Taxation for the period comprises current and deferred tax. Tax
is recognised in the Consolidated Income Statement, except to the
extent that it relates to items recognised in other comprehensive
income or directly in equity.
Current or deferred taxation assets and liabilities are not
discounted.
Current tax is recognised at the amount of tax payable using the
tax rates and laws that have been enacted or substantively enacted
by the statement of financial position date.
Deferred tax
Deferred tax is recognised in respect of all timing differences
that have originated but not reversed at the statement of financial
position date.
Timing differences arise from the inclusion of income and
expenses in tax assessments in periods different from those in
which they are recognised in the Interim Results. Deferred tax is
measured using tax rates and laws that have been enacted or
substantively enacted by the period end and that are expected to
apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are
recognised only to the extent that it is probable that they will be
recovered against the reversal of deferred tax liabilities or other
future taxable profits.
Hire purchase and leasing commitments
Rentals paid under operating leases are charged to the Statement
of Income and Retained Earnings on a straight-line basis over the
period of the lease.
Pension costs and other post-retirement benefits
The Group operates a defined contribution pension scheme.
Contributions payable to the Group's pension scheme are charged to
the Statement of Income and Retained Earnings in the period to
which they relate.
Employee benefits
The Group provides a range of benefits to employees, including
annual bonus arrangements, paid holiday arrangements and defined
benefit and defined contribution pension plans.
Short term benefits, including holiday pay and other similar
non-monetary benefits, are recognised as an expense in the period
in which the service is received.
2. ACCOUNTING POLICIES - continued
The Group operates a number of country-specific defined
contribution plans for its employees. A defined contribution plan
is a pension plan under which the Group pays fixed contributions
into a separate entity. Once the contributions have been paid the
Group has no further payment obligations. The contributions are
recognised as an expense when they are due. Amounts not paid are
shown in accruals in the balance sheet. The assets of the plan are
held separately from the Group in independently administered
funds.
The Group operates a number of annual bonus plans for employees.
An expense is recognised in the profit and loss account when the
Group has a legal or constructive obligation to make payments under
the plans as a result of past events and a reliable estimate of the
obligation can be made.
The Group provides share-based payment arrangements to certain
employees. Equity-settled arrangements are measured at fair value
(excluding the effect of non-market based vesting conditions) at
the date of the grant. The fair value is expensed on a
straight-line basis over the vesting period. The amount recognised
as an expense is adjusted to reflect the actual number of shares or
options that will vest.
Where equity-settled arrangements are modified, and are of
benefit to the employee, the incremental fair value is recognised
over the period from the date of modification to date of vesting.
Where a modification is not beneficial to the employee there is no
change to the charge for share-based payment. Settlements and
cancellations are treated as an acceleration of vesting and the
unvested amount is recognised immediately in the income
statement.
3. ADJUSTED EARNINGS PER SHARE
The Directors believe adjusted earnings per share is a better
representation of underlying business performance after allowing
for significant, non-recurring costs, not related to core
activities.
The full year to March 2023 was primarily impacted by costs
associated with the IPO in November 2022 and a share option charge
associated with the employee share option scheme under FRS 102,
section 26.
This creates an alternative performance measure which better
reflects a fair estimate of ongoing profitability and performance.
The calculated Adjusted EBITDA for the accounting periods shown is
as follows:
30 Sep 30 Sep 31 Mar
2023 2022 2023
Reported Profit 541,009 209,242 60,303
Depreciation 53,124 28,563 52,624
Interest 26,708 20,531 77,998
Tax 165,709 46,616 19,842
Statutory EBITDA 786,550 304,952 210,767
--------------------------- -------- -------- ----------
Adjust for non-operating
items
IPO related and other
one off costs 0 107,689 790,556
Costs related to share
options 0 119,487 360,443
Loss on revaluation of
investment property 0 0 170,620
Adjusted EBITDA 786,550 532,128 1,532,386
--------------------------- -------- -------- ----------
4. EARNINGS PER SHARE
Basic earnings per share is calculated by dividing the earnings
attributable to ordinary shareholders by the weighted average
number of ordinary shares outstanding during the period.
Diluted earnings per share is calculated using the weighted
average number of shares adjusted to assume the conversion of all
dilutive potential ordinary shares.
Underlying EPS is calculated using underling EBITDA, which
excludes costs relating to the IPO and share adjustments.
30 Sep 30 Sep 31 Mar
2023 2022 2023
Basic EPS
Profit per interims 541,009 209,242 60,303
Weighted average number
of shares 10,510,093 10,000,000 10,053,619
Earnings per share (Pence) 5.15 2.09 0.60
----------- ----------- -----------
Fully Diluted EPS
Profit per interims 541,009 209,242 60,303
Weighted average number
of shares 10,701,978 10,000,000 10,417,424
Fully Diluted Earnings
per share (Pence) 5.06 2.09 0.58
----------- ----------- -----------
Underlying EPS
Adjusted EBITDA 786,550 532,128 1,532,386
Depreciation -53,124 -28,563 -52,624
Interest -26,708 -20,531 -77,998
Underlying profit before
taxation 706,718 483,034 1,401,764
Taxation -165,709 -91,776 -266,335
Underlying earnings 541,009 391,258 1,135,429
Weighted average number
of shares 10,510,093 10,000,000 10,053,619
Underlying Earnings
per share (Pence) 5.15 3.91 11.29
----------- ----------- -----------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXKZMGZNMZGFZM
(END) Dow Jones Newswires
December 04, 2023 02:00 ET (07:00 GMT)
One Health (AQSE:OHGR)
Historical Stock Chart
From Oct 2024 to Nov 2024
One Health (AQSE:OHGR)
Historical Stock Chart
From Nov 2023 to Nov 2024
